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Abstract

This retrospective study shows that the majority of patients’ correlations between
PSA and Testosterone during the on-treatment period is at least 0.90. Modelbased duration calculations to control PSA levels during off-treatment are provided. There are two pairs of models. In one pair, the Generalized Linear Model
and Mixed Model are both used to analyze the variability of PSA at the individual patient level by using the variable “Patient ID” as a repeated measure. In the
second pair, Patient ID is not used as a repeated measure but additional baseline
variables are included to analyze the variability of PSA.
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Introduction According to the American Cancer Society’s estimates for prostate cancer in the
United States in 2015, there are about 220,800 new cases of prostate cancer and about 27,540
deaths from prostate cancer each year. It is the second most fatal type of cancer for males, behind
only lung cancer. One out of seven men will get prostate cancer during his lifetime and one in
38 will die of this disease. Available from URL:
(http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics)
1
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[accessed May 4, 2015]
Prostate Cancer (PCa) represents a third of all cancer incidence in men – six-fold that of
leukemia and lymphoma. Most cases are indolent, referring to the number of elderly men who
die with cancer rather than die from it. Huggins, a urological surgeon, reasoned “that rather than
eliminate the male hormones, what if one tricked the cancer into thinking that the body was
‘female’ by suppressing the effect of testosterone?” This led to synthesizing analogues of
estrogen, the female hormone, which resulted in the most widely used drug, DES, or Premarin, in
order to stop the production of testosterone in patients with prostate cancer, Mukherjee (2010).
“PCa cells at an early stage also have a dependence on androgen, androgen ablation results in the
degeneration of prostate tumor. The major treatment for advanced PCa has been endocrine
(hormone) therapy. If androgen deprivation (AD) is overly prolonged (continuous androgen
suppression, CAS), the AD cells change to androgen – independent (AI) cancer cells which are
resistant to hormone therapy. It is possible to suspend androgen suppression by simply stopping
the administration of the hormone based drugs. Building on this concept, intermittent androgen
suppression (IAS) was proposed, Hirata, et al (2012). In IAS treatment, when an upper threshold
value of PSA is reached, therapy is started while when the PSA level decreases to a lower
threshold level, treatment is stopped. PCa can be treated by one or more of the following
methods, depending upon the stage of PCa: 1.Surgery, 2. Radiation Therapy, 3. Hormone
Therapy, 4. Chemotherapy.
It is noted that hormone therapy cannot cure PCa. Instead, it slows the growth of PCa. It is
mostly used in last stages, i.e., C&D. It decreases the production of testosterone. Since we are
investigating IAS treatment in this paper, it is worth knowing the effectiveness of this treatment.
The efficacy of IAS was demonstrated in animals, Bruchovsky et al. (1990) and Akakura et al.
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(1993). The clinical efficacy of IAS for human patients has been studied by many research
groups, Abrahamsson (2010). One hundred and three patients after radiation therapy for locally
advanced PCa, eligible for IAS were treated for 6 years. The time off treatment averaged 35% of
the total time cycle during an average of 5 cycles. Prostate volume was reduced by 40% in cycle
1 and by 34% in cycle 2, but there was no decrease in subsequent cycles Bruchovsky et al.
(2006). It was reported by Hussain M, et al. (2013) that a total of 1535 patients were analyzed to
compare IAS versus CAS therapy in PCa. Of these, 765 were randomly assigned to CAS and 770
to IAS. The mean follow up period was 9.8 years. The IAS group was associated with better
erectile function and mental health at 3 months but not thereafter. There was a 20% greater risk
of death with IAS therapy. However, no significant inferiority of IAS therapy was observed. IAS
therapy resulted in small improvements in quality of life. These conclusions should be taken into
consideration in recommending IAS or CAS therapy to patients. It is also observed that IAS
treatment on PCa shows remarkable results at the beginning of treatment, but cancer cells
frequently grow during long term CAS therapy. IAS is effective for some patients but not others.
To understand these problems, mathematical models have been developed to explain the
mechanism of IAS and CAS. A review of various mathematical models is made, Hirata, et al
(2012). Out of all these models, the piecewise linear model is preferred. It compares the
prediction of the outcome of IAS and CAS hormone therapy and predicts the actual quantitative
changes in prostate specific antigen (PSA), which is a tumor marker, Hirata et al. (2010-1).
However, no optimal scheduling for IAS was done in this paper. The method of optimal
scheduling was explained later by Hirata et al. (2010-2). This optimal scheduling determines a
recommended duration for the ‘on-treatment period’ and the ‘off-treatment period’ such that
PSA declines.
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Many statistical models in prostate research can be found in the literature. Some recent ones used
are tests for trend and multivariable logistic regression analyses, Bhindi et al. (2015). The usual
two-sided statistical tests and area under the curve methods are used by Bryant et al. (2015).
Multivariate random-effects meta-analysis models are used by Chen et al. (2015). Survival
analysis based methods in particular Kaplan-Meier analysis and one variable and multivariable
Cox proportional hazards models are also used by Moschini et al. (2016). A statistic shape model
was used recently, Tao et al. (2015). Although many statistical models exist in the literature, to
the best of the knowledge of the present authors, no statistical model investigating the optimal
scheduling of on- and off-treatment duration has yet been developed. Mathematics based models
to study the problem of optimal scheduling has been looked at by Hirata et al. (2010-2) but this
manuscript is the first of its kind using the specified statistical models to study this issue. For
illustration, consider a prostate cancer patient who has been under the treatment of an oncologist.
The oncologist puts the patient under treatment, say, for about two months. The patient reports to
the oncologist after two months and his observed PSA has, say, come down below the normal
level. Thus, the oncologist decides to discontinue his treatment for say two or three months due
to improvement of the patient’s quality of life. However, it is quite likely that during this off
treatment period his PSA rises significantly due to lack of continuous monitoring and therapy.
Therefore, in this manuscript, we want to find the optimal duration for on- and off-treatment
periods so that PSA value does not go much beyond the final PSA reading during on-treatment.

Methods. We use the Generalized Linear Modeling and Mixed Modeling approaches to build
our statistical models. The Generalized Linear Model is the generalization of linear regression
models that allows a wide range of error distributions and is expressed in terms of the mean
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function. Mixed Model is a linear model that has coefficients which may be fixed or random.
The clinical data we use consists of 109 patients on hormone therapy monitored over a period of
six years. The patients at the end of the study were classified as non-eligible (6), non-compliant
(5), loss to follow up (5), inter current illness (2), adverse experience (2), and administrative /
other reasons (4). The preceding 24 patients were excluded from the modeling study. The
remaining, were classified as death (17), treatment failure (26), an end of study (42).
These remaining eighty five patients were randomly divided into two groups. Group 1 patients’
data (43) is used for model development and the remaining patients’ data (42) as Group 2 for
prediction. In Group 1 we focus on those patients for whom the hormone therapy was completed
(21 patients). This means that the patients successfully reached the end of the study. This focus
was chosen to find the ideal model for IAS therapy. Thus we developed four models as described
below in this section. These models are used to predict PSA for all the patients especially those
for whom the therapy did not work in Group 1and all the patients in Group 2. The effectiveness
of the models is evaluated by predicting the PSA for all the eighty-five intent-to-treat patients
and comparing them with their actual PSA reading especially for patients who did not reach the
end of study of the IAS therapy. This comparison helps us to determine what it would take for
patients who did not reach the end of study such as death to have shown better results.
The Group 1 randomly obtained data for modelling is studied using exploratory data analysis for
any relationship among the different available variables as preparation for analysis. Exploratory
data analysis summarizes the basic characteristics of the variables mainly using graphical
methods. This enables us to observe the high correlation between testosterone and PSA during
the on-treatment period among almost all Group 1 patients. In order to emphasize the importance
of this observation and its generalizability, the same correlation is examined and computed over
5
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all the available 109 patient data. Due to missing data this computation shows, correlation for
the reduced number of 95 patients as can be seen from the Figure 1 below. Pareto Chart is a bar
graph with descending order of the values of the variable.

Figure 1. Pareto Chart showing positive linear relationship between PSA and Testosterone
during IAS for on-treatment period.
As is evident from the graph, much more than majority of the patients’ correlation of PSA and
Testosterone during on-treatment period is above 90%. This is useful because it demonstrates
that during the on-treatment period testosterone behaves as a surrogate variable to PSA. For a
given patient, one could use linear regression to predict his PSA reading from testosterone
readings or vice versa, with fairly reasonable accuracy.
The data can be viewed as consisting of two parts: one is the data collected at the start of
the study, i.e., baseline data, and the other is longitudinal data observed until the end of six year
study. The variables in the longitudinal data consist mainly of the variables such as File ID
(identifying the patient), Site, the geographical site of the clinic where the patients visited, Date
6
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of the visit, Week of the visit, PSA, Testosterone, Period, which is either 1 – on treatment, or 0 –
off treatment and Cycle – the number of consecutive on- plus off-treatment periods the patient
had gone through. The models are developed based on data from those patients in Group1 who
successfully completed IAS treatment because we were searching for the “perfect PSA model”
which would capture the behavior of the PSA in terms of the longitudinal covariates (i.e.,
independent variables that explain the variability in the dependent variable PSA). This focus was
achieved by excluding in the perfect PSA model search, those patients who did not complete the
therapy or those who died. Thus, our focus of developing the perfect PSA model was restricted
to 21 patients from within Group 1 – the modeling group for whom the intermittent therapy was
successfully completed. Since baseline data was observed only once there is no variability in
these variables over time and hence they do not show up in the repeated measure models.
Repeated measure models take into account the measurements which change with time. Also
chemistry and hematological data was excluded from the search of the perfect PSA model.
The backward procedure which consists of including all the variables in the model and then
eliminating the ones that are least significant based on p-values was used to arrive at the models.
To avoid the problem of multicollinearity between covariates, we included only Date but not
Week in the model. The data consisted of 1,522 records of which 1,116 are used but 406 are
excluded due to missing observations. The error distribution was taken to be normal. Since some
PSA readings would suddenly be very large and could also go as low as zero for a patient, in
order that the error distribution could be taken to be normal, a natural log transform of 1+PSA is
used. Thus the backward procedure using ‘proc genmod’ code within SAS program, with File
ID as the repeated measure, and unstructured covariance matrix specification, yielded
convergence of the algorithm for computing parameters with Generalized Estimating Equation
7
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(GEE). Fit Criteria reading of QIC (Quasi-likelihood under the Independence model Criterion,
Pan, 2001) = 1115.0862 and QICu = 1142.0000, the latter in addition penalizes in terms of the
number of parameters used in the model (there is penalty for incorporating more parameters).
These fit criteria were also used to get the best model by choosing the ones that have low fit
values. The Table 1 below summarizes the results of testing the null hypothesis that the
regression coefficient parameter of the model is zero against the alternative that it is not zero,
from SAS output. The parameter estimate is the value of the function of the data estimating the
regression coefficient of the Generalized Linear Model. The estimated standard deviations of
these estimators are the standard errors (S.E.). The Z-statistics values are the estimate of the
parameters divided by the corresponding S.E., which is therefore not specified in the Table 1
below, but give rise to the two-sided p-values from the standard normal distribution. The
Generalized Linear Model in Table 1 was fitted with weights equal to the reciprocal of the
sample variance. This model is identified from here onwards in this paper as Model 1. Note that
by default SAS analysis binary variable in the numerical order, i.e., Period is taken by SAS
program as an indicator variable of off-treatment because it is represented by “0”. The summary
of the results from SAS is as follows:
Table 1: Analysis Of GEE Parameter Estimates (Model 1)
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Parameter

Parameter Estimate

Standard Error

P-value

-16.8731

1.4758

<.0001

File ID

1.0024

0.1488

<.0001

= 14
13

0.2373

0.0774

0.0022

= 15

1.7514

0.1329

<.0001

= 22

0.4611

0.0346

<.0001

= 28

1.0103

0.1099

<.0001

= 31

0.7926

0.0290

<.0001

= 37

1.2891

0.1131

<.0001

= 40

0.7517

0.0326

<.0001

= 50

1.6079

0.1022

<.0001

= 58

0.6035

0.1133

<.0001

= 60

0.8143

0.1237

<.0001

= 61

0.4651

0.0531

<.0001

= 62

0.4945

0.0916

<.0001

= 77

0.8321

0.1119

<.0001

= 79

1.3575

0.0857

<.0001

= 87

1.2623

0.0970

<.0001

= 95

-0.4218

0.0161

<.0001

= 96

0.1008

0.0280

0.0003

= 97

0.3474

0.0214

<.0001

= 104

0.1969

0.0290

<.0001

= 106

0.0000

0.0000

.

Testosterone

0.1693

0.0133

<.0001

Period = 0

-0.0459

0.0394

0.2448

Period = 1

0.0000

0.0000

.

Testosterone•(Period = 0)

-0.0913

0.0113

<.0001

Testosterone•(Period = 1)

0.0000

0.0000

.

Date

0.0013

0.0001

<.0001

Cycle

-0.7891

0.0920

<.0001

Intercept

All the covariates tried in the model are File ID, Date, Testosterone, Cycle, Period, including the
9
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interaction term between Testosterone and Period, turned out to be significant. Note that
although Period by itself did not show significant, however, as was expected from the Pareto
Chart Figure 1 the interaction between Testosterone and Period is significant and hence all the
corresponding main effect covariates are also retained in the model. The final Model 1 is then
given by the linear combination of I{File_ID = i} with their corresponding parameter estimates
along with the linear combination of Testosterone, one minus Period (1-Period), Testosterone
multiplied by (1-Period), Date, and Cycle. The residual analysis shows that the histogram,
boxplot, and normal probability plot of residuals are all indicative of the normal error
distribution is the valid assumption. Furthermore, for the residual data, the Kolmogorov-Smirnov
test statistics value D = 0.026633, yielding a p-value of 0.0532 > 0.05. All the graphs and this
test indicate that the normal error with repeated measure design gives a good fit and especially so
because the GEE parameter estimation method converged. All four models mentioned in this
paper yield similar residual graphs as previously discussed. This model, which decides the
inference of the parameters based on deviance analysis, is what we term as the first model
(Model 1). Similarly, a model with the same weights as before was developed with similar
answers using the SAS procedure of ‘proc mixed’, which develops the estimation using the
Maximum Likelihood Method and the analysis of variance with covariance structure for the
repeated variable File ID taken to be AR(1) (autoregressive with one parameter), with the
following results in Table 2 to 5. This model from here onwards will be referred to as Model 3 in
this paper, which is similar in results to Model 1. The Z-values in Table 2 are as defined in Table
1 and are therefore suppressed.
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Table 2. Covariance Parameter Estimates (Model 3)
Covariance Parameter

Subject

AR(1)

File ID

Residual

Parameter Estimate

Standard Error P-values

0.8787

0.01499

<.0001

0.02214

0.002677

<.0001

The following fit statistics were used to come up with the best Mixed Model. None of the
random coefficient terms turned out to be significant. However Model 3 does confirm the results
of Model 1 above because they give rise to very similar equations.
Table 3. Fit Statistics (Model 3)
-2 Log Likelihood

698.7

AIC (smaller is better)

754.7

AICC (smaller is better)

756.2

BIC (smaller is better)

698.7

In Table 4 below, the t – values similar to the Z-values are defined to be the parameter estimate
divided by S.E. with degrees of freedom (D.F.) equal to 1090, except when estimating the
intercept which has zero degrees of freedom and hence no p-value associated with it.
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Table 4. Likelihood Solution to the Parameters of Fixed Effects (Model 3)
Effect of the Covariate
Intercept
File_ID

Parameter

Standard Error

P-value

-12.9891
Estimate
1.2965

1.5915

.

0.5625

0.0214

= 14
13

0.1474

0.3900

0.7056

= 15

1.6463

0.4748

0.0005

= 22

0.2858

0.3604

0.4280

= 28

1.2204

0.5953

0.0406

= 31

0.4906

0.4539

0.2800

= 37

1.4391

0.4876

0.0032

= 40

0.3650

0.3632

0.3151

= 50

1.6996

0.5665

0.0028

= 58

0.6617

0.4354

0.1289

= 60

1.2435

0.5546

0.0252

= 61

0.4188

0.3960

0.2905

= 62

0.7849

0.6284

0.2119

= 77

0.8136

0.5218

0.1192

= 79

1.4010

0.4182

0.0008

= 87

1.5195

0.6358

0.0170

= 95

-0.1619

1.2573

0.8976

= 96

-0.02859

0.3517

0.9352

= 97

0.09776

0.3841

0.7991

= 104

0.2776

0.4683

0.5534

Testosterone

0.1306

0.003837

<.0001

Period = 0

0.01458

0.04122

0.7235

Period = 1

0

.

.

Testosterone•Period = 0

-0.09184

0.005274

<.0001

Testosterone•Period = 1

0

.

.

Date

0.001052

0.000113

<.0001

Cycle

-0.9285

0.07297

<.0001
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Although some of the p-values corresponding to File ID in Table 4 do not show up to be
significant, however, in the Type III analysis of variance results in Table 5 below shows File ID
to be significant. The Mixed Effects Model can show random coefficients (as opposed to fixed
effects coefficients shown in Table 5 below) when significant.

Table 5. Type 3 Tests of Fixed Effects Parameters (Model 3).

Effect of Covariate
File_ID

Numerator D.F. Denominator D.F.

F Value

P-value

20
D DFDD DF
1

1090

3.16

<.0001

1090

903.89

<.0001

Period

1

1090

0.13

0.7235

Testosterone*Period

1

1090

303.25

<.0001

Date

1

1090

87.43

<.0001

Cycle

1

1090

161.93

<.0001

Testosterone

Thus Model 3, whose fit converged, gives similar results to the previous model and these models
confirm each other’s results because they give rise to very similar equations. The other models
developed are those that do not use the File ID as a repeated measure but include all the
meaningful baseline variables in a backward procedure to obtain two models (Model 2 and
Model 4), one using ‘proc genmod’ and the other using ‘proc mixed’ through SAS, respectively.
Similarly as before, both models with normal errors give analogous results to each other. In fact
Model 4 residual analysis showed similar residual plots with only two mild outliers but the
Kolmogorov-Smirnov test statistic D = 0.028869, p-value > 0.1500, Cramer-von Mises statistics
W-Sq = 0.055751, with p-value > 0.2500 and Anderson-Darling statics A-Sq = 0.453359, with pvalue > 0.2500, which are obviously not significant at the 5% level (i.e., normality of the
residuals cannot be rejected). All the graphs and the tests indicate that the normal error for the
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error distribution gives a good model fit. The validity of Model 4 is also confirmed because the
algorithm to find Maximum Likelihood Estimates converged.
Although many meaningful and useful baseline variables related to prostate cancer study were
taken into account, many of these variables had either missing data or did not show much
variability in the data and therefore did not show up significant in the model. However, baseline
variables such as registered age (Reg_Age), Body Mass Index (BMI), Blood Pressure (BP),
Gleason Score (GleasonS), Radiation therapy (Rad_t), Total Prostate Volume (TPV) and number
of Positive Cores (PosCores) showed up to be significant in these models to explain the
variability in natural log of PSA+1 in addition to Testosterone, Period, Testosterone interaction
with Period, Date and Cycle. Also, of the 1522 records of successful therapy patients in Group 1,
only 481 records were used to develop these models (Model 2 and Model 4) due to missing
observations in the baseline variables.
All four models are used to analyze the data from patient # 62 as an example. One could have
used any other patient for whom the model fit is close. The results are as follows.

14
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Figure 2. Plot of PSA and Predicted PSA versus Date (Model 1).
The PSA readings as a function of time during any given cycle form an elbow or V – shape, the
left line of the “V” being formed by PSA readings during on-treatment period and the right line
of the V by that of the off-treatment period. The Model 1 equation is described by:
1+PSA(t) = f  X1 , X 2 (t ), X 3 (t ), X 4 (t ), X 5 (t ), t  ,
where X1 = is the linear function of File_ID’s, X 2 (t ) = Testosterone, X 3 (t ) = 1-Period, X 4 (t ) =
Testosterone multiplied by (1-Period), and X 5 (t ) = Cycle, and t, which represents time, i.e., the
variable Date, respectively. This function f  X1 , X 2 (t ), X 3 (t ), X 4 (t ), X 5 (t ), t  also known as the

15
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conditional expectation of response is
= exp −16.8731 + X1 + 0.1693 X 2 (t ) − 0.0459 X 3 (t ) − 0.0913 X 4 (t ) − 0.7891X 5 (t ) + 0.0013t.
Here,

X 1 = 1.0024 I{File_ID=13} +0.2373I{File_ID=14} +1.7514 I{File_ID=15} +0.4611I{File_ID=22}
+1.0103I{File_ID=28} +0.7926 I{File_ID=31} +1.2891I{File_ID=37} +0.7517 I{File_ID=40}
+1.6079 I{File_ID=50} +0.6079 I{File_ID=58} +0.8143I{File_ID=60} +0.4651I{File_ID=61}
+0.4945I{File_ID=62} +0.8321I{File_ID=77} +1.3575 I{File_ID=79} +1.2623I{File_ID=87}
−0.4218I{File_ID=95} +0.1008 I{File_ID=96} +0.3474 I{File_ID=97} +0.1969 I{File_ID=104}.
Note that I A = 1, if event A is true and 0, otherwise. A time t1 is taken to be a time point
between 17-May-96 to 2-Aug-96 taken from the left section of the V –shaped PSA graph, when
Period is 1, i.e., on-treatment at time t1, (1+PSA)(t) is written as (1+PSA)ON(t1). Also, PSA
readings during on-treatment are represented as PSA-ON. Similarly, when Period is taken to be
0, i.e., off-treatment at time t2 it is (1+PSA)OFF(t2), where t2 is taken to be a time point between
13-Jun-97, 10-Nov-97, taken from right section of the V-shaped PSA graph. Also, PSA readings
during off-treatment are represented as PSA-OFF.
Note that, since PSA during on-treatment is generally declining as a function of time and that
PSA during off-treatment is inclining with a positive slope. Optimal scheduling for a fixed cycle
is taken to be that period under which PSA-OFF ≤ PSA-ON. Optimal period is reached when
PSA-ON = PSA-OFF because we do not want the patient to be too long on- off-treatment. If the
patient is too long on- off-treatment then, their PSA will rise, however, we do not want them to
be on- off-treatment period for too short of a time. Shorter off-treatment period translates in the
next cycle into longer on-treatment which in turn would imply longer lower quality of life.
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To achieve the preceding optimal condition, we consider the following quotient to be equated to
‘1’:
(1+PSA)ON(t1) / (1+PSA)OFF(t2) =
Exp { 0.0459 + 0.1693 • (Test-ON – Test-OFF) + 0.0913 • Test-OFF + 0.0013 • (t1 – t2)},

where Test-ON and Test-OFF are testosterone variable during on- and off-treatment periods,
respectively. The largest empirical duration of days between t2 and t1 computes to be 543 days
using the ranges of times specified above.
Let PSA-ON = PSA-OFF, which implies
N - 0.0013 • (D) = 0,

(1)

where D = t2 – t1 and N = 0.0459 + 0.1693 •Test-ON - 0.078 • Test-OFF. Thus D = N/0.0013.
Test-ON = 10.75 is an average reading in the range of t1 specified above during Cycle 1, for
patient 62. Similarly, Test-OFF = 17.26 an average reading in the range of t2 specified above.
Thus N = 0. 519595. Therefore, from equation (1) D = N/0.0013 = 400 days. The same
procedure as described above for Cycle 1 can be followed within each of the Cycles 2 and 3.
Model 2 equation is given by f  X1 (t ), X 2 (t ), X 3 (t ), X 4 (t ), X 5 , X 6 , X 7 , X 8 , X 9 , X10 , X11, t  similar
to the one described in Model 1. Here, f is 1+PSA as a function of Testosterone, 1 - Period,
Testosterone multiplied by (1-Period), Cycle, which itself are functions of t, i.e.,

X1 (t ), X 2 (t ), X 3 (t ), X 4 (t ), respectively. Also, X 5 , X 6 , X 7 , X 8 , X 9 , X10 , X11 , represent the baseline
variables registered age Reg_Age, body mass index BMI, blood pressure BP, Gleason score
GleasonS, duration of radiation therapy Rad_t , total prostrate volume TPV, and positive cores
PosCores, respectively. Thus,
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f  X1 (t ), X 2 (t ), X 3 (t ), X 4 (t ), X 5 , X 6 , X 7 , X 8 , X 9 , X10 , X11, t  =
−23.6633 + 0.1786 X1 (t ) − 0.2112 X 2 (t ) − 0.0956 X 3 (t) − 0.8294 X 4 (t) + 0.0011t

exp 
.
+0.1198 X 5 + 0.066 X 6 − 0.0519 X 7 + 0.2004 X 8 + 0.0493 X 9 + 0.0299 X10 + 0.3669 X11 
Following similar calculations as in Model 1 above,
(1+PSA)ON(t1) / (1+PSA)OFF(t2) = Exp { 0.2112 + 0.1786 • (Test-ON – Test-OFF) + 0.0956 •
Test-OFF + 0.0011 • (t1 –t2)}.
Letting PSA-ON = PSA-OFF, implies
N - 0.0011 • (D) = 0,

(2)

where N= 0.2112 + 0.1786 •Test-ON - 0.083 • Test-OFF and D = t2 – t1. Thus D = N/0.0011.
Again, Test-ON = 10.75 and Test-OFF = 17.26. Thus N = 0.69857. Therefore from equation (2)
D = N/0.0011 = 635 days. The computations for Models 3 and 4 are similar to Models 1 and 2,
respectively. The models 1-4 based duration calculations when PSA-ON is set equal to PSA-OFF
are 400, 635, 685 and 541, respectively. The duration results for the four models and for Cycles
1, 2 and 3 are presented in Table 6.
Table 6. Durations in days
Predicted Duration
Empirical Duration
1
2
3
4
Cycles\Models
1
400 635 685 541
543
2
79
239 251 168
540
3
1099 1514 1138 1370
763

As an illustration for using this predicted duration, consider the predicted duration of say 400
days and suppose that the patient was put on treatment for 250 days by the end of which his PSA

18
https://biostats.bepress.com/harvardbiostat/paper214

value came down to a normal level. The patient has to be then put on- off-treatment for the
remaining 150 days. Then the new cycle starts.
Now to see the predictive power of the fitted models, we consider patient with File ID 3. This
patient died during the treatment period. The predicted PSA values based on the first two models
for this patient versus actual PSA readings are shown in Figure 3 below. Results for the
remaining two models will be similar.

Figure 3. Based on a) Model 1 (left) and b) Model 2 (right).

We notice consistently that both models predict that the PSA reading for patient 3 should have
been much lower across the course of the intermittent therapy, with very little overlap between
the actual and the predicted PSA. Note that similar predictions are seen for all patients for whom
the treatment failed or that died during the IAS six year therapy.
Discussion. In order to compare the finding of our research with those of Hirata et al. (2010-2,
Section V, Numerical Examples and Figure 4), we have the following observations:

19
Hosted by The Berkeley Electronic Press

In their research three patient cases are considered. The third patient whose model based PSA is
continuously rising, CAS is recommended without mentioning the therapy’s impact on quality of
life or the impact of other covariates such as testosterone on his monitored PSA. The first patient
whose model based PSA is cyclically declining trend, an optimal schedule of first 259 days of
on-treatment followed by 7 days of off-treatment is recommended, without regard to the patient’s
quality of life. Also, it is well known that PCa cells convert into AI cell over prolonged CAS.
This treatment regime puts the patient on- off-treatment only for a week (compared to 259 days
of on-treatment), which is almost a CAS therapy. Thus, on- and off-treatment periods’ cycles of
266 days would continue. In case of the second patient whose model PSA is cyclically rising an
optimal schedule cycles each of length of 721 days is recommended. An initial on-treatment
period of only 168 days (about a half year), followed by 553 days off-treatment is considered
here. It is not clear why such a period of more than a yearlong off-treatment is justifiable when
the model clearly is predicting a growing trend in the patient’s PSA. In view of the above
observations no meaning comparison can be reported.
Conclusion. We observed in this study that a large majority of patients’ correlations between
PSA and Testosterone during the on-treatment period of IAS were at least 0.90. The length of
time duration for a treatment cycle, while taking account of when the treatment should be “on”
and when it should be “off,” is calculated from a model, which is a useful application. To
illustrate this, consider a patient under treatment. If his PSA level is low during on-treatment,
when his therapy is stopped, then the number of days during the off-treatment period should be
such that on-treatment days combined with off-treatment days (during treatment Cycle 1) should
be no more than 541 days, according to Model 4 (or the largest empirical duration of 543 days).
At this junction we would like the Oncologist to decide, how long the on-treatment period should
20
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last depending upon the opinion of the patient in terms of his quality of life. Then, the duration of
the off-treatment period can be determined by subtracting the on-treatment period from the 541
days of the total cycle time period. After 541 days, the PSA is likely to go up; therefore, the
oncologist should put him on treatment until the PSA level comes down to the desired value in
the next cycle.
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